Formycon Shares Hit Fresh Annual Low Amid Mixed Signals

Investors in Formycon are currently facing a contradictory set of developments. The stock price plunged to a new 52-week low on Friday, shedding over 7% to close at €17.02. This latest drop brings the year-to-date decline to more than 35%, as the market reacts sharply to recent corporate announcements.

Administrative Delay Overshadows Operations

A significant factor in the recent sell-off is a postponement in the company’s reporting schedule. Formycon has delayed the publication of its audited annual financial statements for 2025. Originally slated for March 26, the release has been pushed to April. Management cites the group-wide implementation of a new financial planning system as the cause, stating that the associated coordination and validation efforts for the final accounts are taking longer than initially planned.

This administrative hurdle has introduced short-term uncertainty, which appears to be weighing more heavily on investor sentiment than positive long-term strategic news. The market is now looking ahead to April, when the company is scheduled to announce its results for the fourth quarter of 2025 alongside the final annual report. These figures will be scrutinized to confirm that the fundamental business progress remains on track despite the IT-related delay.

Should investors sell immediately? Or is it worth buying Formycon?

Patent Settlement Clears Path for Key Biosimilar

On a strategically positive note, Formycon reached a critical settlement on March 19 with industry giants Regeneron and Bayer. The agreement resolves all patent disputes and paves the way for the European launch of its Aflibercept biosimilar, FYB203, starting in May 2026.

The conclusion of this litigation through a comprehensive settlement and licensing agreement provides the company’s leadership with crucial legal clarity and planning security for the product’s commercial rollout. This development marks a substantial step forward for one of Formycon’s most important pipeline assets.

For now, however, the immediate concerns regarding financial reporting have taken precedence in the market’s assessment, driving the share price to its lowest point in a year.